Obesity, increasing worldwide, is common in patients undergoing hematopoietic cell transplantation (HCT). This complex physiological state may alter the outcome of cancer therapies by many mechanisms including direct effects on pathogenesis, host responses to disease and altered pharmacology of chemotherapy. Obesity has been associated with multiple adverse health outcomes. Reports of obese patients undergoing HCT are challenging to interpret because of the heterogeneity of obesity definitions, underlying diseases, graft sources and chemotherapy regimens employed. Compared with normal-weight patients, it appears that obese patients undergoing allogeneic HCT have a higher risk of non-relapse mortality and inferior survival whereas those receiving autologous HCT appear to have equivalent outcomes. These findings are also difficult to interpret because there is no consistent standard for calculating chemotherapy dose in this group and future studies on specific regimens in this population are urgently needed. Patients who have undergone bariatric surgery may be at risk for unexpected events because of impaired nutritional state and altered pharmacokinetics of oral drugs. We recommend that future studies utilize more consistent and biologically relevant definitions of obesity and that the pharmacokinetics and pharmacodynamics of specific conditioning regimens be studied. Until more evidence is available, a rationale is presented for dosing based on adjusted body weight. Moreover, recommendations are provided to guide future research efforts based on more definitive measurements of body fat and its distribution available through modern quantitative imaging techniques using dual energy X-ray absorptiometry or magnetic resonance imaging scanning.
INTRODUCTION
Obesity rates are increasing throughout the world and especially in the United States where its prevalence among adults increased from 15% in 1980, to 23% in 1998, 33 .8% in 2008, and is projected to reach 42% by 2030. 1, 2 Obesity is associated with higher morbidity and mortality, accounting for approximately 280 000 deaths annually in the United States, in part due to the obesityassociated increased risk of diabetes mellitus, heart disease, stroke and cancer. 3 Among cancer patients, obesity is associated with a greater overall and cancer-specific mortality. 4, 5 Obesity also may affect prognosis in cancer patients by promoting tumor growth and progression, by altering pharmacokinetics and pharmacodynamics of therapeutic agents and by contributing to chemotherapy toxicity. Thus, the current obesity pandemic is likely to provide new challenges to oncologists and institutions providing cancer care in terms of therapeutic strategies, supportive care and institutional resources.
Obesity-associated challenges in patient management are of particular concern for programs performing hematopoietic cell transplant (HCT) for several reasons. First, the risk of developing specific malignancies, including several commonly treated with HCT, is frequently elevated in the obese. For example, many but not all studies demonstrate increased risk for CML, CLL, nonHodgkin and Hodgkin lymphoma and plasma cell myeloma (PCM) in the obese. [5] [6] [7] [8] [9] [10] [11] Second, the overall increase in obesity, in general, suggests that it will become a more common comorbidity in patients presenting for HCT even in the absence of increased risk. Third, studying the impact of obesity upon patients undergoing HCT has been challenging due to variability in obesity definitions across studies and inconsistent conclusions as to whether obesity may or may not adversely affect TRM, mortality or relapse of lympho-hematopoietic malignancies. 12 The increasing incidence of obesity and the probability that the number of obese candidates requiring HCT will expand, as well as the unique problems experienced by these patients indicate that focused attention and special consideration be given to the planning and implementation of HCT in the obese.
In this review, we address two fundamental issues when approaching the obese HCT patient: (1) pretransplant risk assessment and (2) chemotherapy dose calculation to balance efficacy and safety. In addition, we will discuss issues relevant to HCT in patients who have undergone bariatric surgery. We will further discuss the usefulness of exercise in the obese transplant patient. Finally, we will provide recommendations for management and summarize current and future research priorities.
Homeostasis of fat
Obesity is a chronic disease resulting from an imbalance of energy intake and energy utilization, with profound influences by environment, physical activity, psychosocial factors and even sleep, 13, 14 leading to expansion of the size and number of fat cells in adipose tissues and their distribution throughout the body.
Although once considered an inactive energy storage depot for accumulating lipids, adipose tissue now is recognized as an endocrine organ in its own right, as well as a site of intense metabolic activity. This tissue is the source of synthesis for systemically circulating adipokines such as leptin and adiponectin. These moieties regulate systemic hormone concentrations for insulin, insulin-like growth factor (IGF) and sex steroid levels, all of which may affect normal and tumor cell growth. 17 In addition to adipocytes, adipose tissue contains multiple types of hematopoietic cells that may be relevant to HCT. Hematopoietic stem cells resident in adipose tissue are capable of rescuing lethally irradiated rodents. 18, 19 Adipose tissue also contains resident macrophages which, together with adipocytes, result in local inflammation and secretion of systemic inflammatory cytokines such as TNFa, IL-6 and others. 20 Lastly, adipose tissue is associated with alterations in T cells resident in adipose tissue. 21, 22 These findings suggest that adipose depots in the morbidly obese could be either a reservoir or a sink for transplanted HSC, macrophages and T cells that may impact HCT outcomes either positively or negatively.
It is now clear that different anatomic depots of adipose tissue differ in their impact on hormone metabolism and systemic inflammation. 23 Thus, visceral adipose tissue has been shown to be more metabolically active than peripheral fat; omental fat is more active than the tissue in subcutaneous areas. 24, 25 With respect to HCT, it is important to remember that a major component of adult bone marrow is composed of adipocytes that contribute significantly to the microenvironment in which hematopoietic progenitor cells grow. 26 How these different fat depots influence cancer risk, cancer progression, response to therapy and relapse are areas of intense interest and require careful investigation of their impact on hematologic malignancies and HCT. For example, using in vitro and in vivo model systems to investigate adipocyte interactions with a pre B-cell lymphocytic leukemia model, Behan showed that dietinduced obesity interfered with chemotherapy treatment of leukemia, that fat pads serve as sanctuary sites for leukemia cells and that in in vitro coculture systems, adipocytes alter the balance of drug-induced apoptotic signals and increase cell cycling, which may protect leukemia cells from drugs such as vincristine, doxorubicin, dexamethasone and nilotinib. 27 Obesity definitions and influence of ethnicity The World Health Organization (WHO) defines obesity by the body mass index (BMI) determined as weight in kilograms divided by square of height expressed in meters. 28 Normal BMI is set as 18.5-o25 kg/m 2 , overweight X25.0-o30.0 kg/m 2 , obeseX30.0-o40.0 kg/m 2 and severely obese X40 kg/m 2 . Although these categories provide a rigorous definition of obesity on which much of the literature is now based, differences in size and body fat composition by ethnicity may result in underestimating obesity in Asians when using these ranges and a BMI 425 kg/m 2 defines obesity in Asians and South Asians. 29 Other measurements of obesity sometimes are used to stratify patients for clinical studies and these variations may contribute to different outcomes associated with obesity. Waist circumference and waist:hip ratios are commonly used as measures of obesity. These scales emphasize central or visceral adipose depots, which are more metabolically active than peripheral adipose tissue and consequently are associated with a higher incidence of metabolic syndrome, cardiovascular disease, morbidity and mortality. 30 A waist circumference 488 cm in women and 102 cm in men now defines obesity. 31 In contrast, obesity in Chinese populations is defined as a waist circumference 480 cm in women and 96 cm in men; 32 this measurement may be more useful in the elderly as both body height and non-fat mass decrease with aging. 33 
External imaging
Modern imaging technology provides more accurate approaches to quantitate body fat and characterize its distribution. Total body dual energy X-ray absorptiometry scans, often employed for diagnosing osteoporosis or osteopenia (bone mass), can be used to also distinguish fat mass and lean body mass, assess regional distribution such as central vs peripheral fat and provide quantitative estimates of components and total adiposity. 34 Other techniques, such as magnetic resonance imaging (MRI), now are also used to provide images to quantitate visceral and subcutaneous adipose tissue volume. 34, 35 This latter technique has the advantage of providing three dimensional imaging; as MRI does not utilize ionizing radiation, it can be employed repeatedly to follow changes without concern for radiation exposure. Our further recommendations for identifying obesity and the use of imaging technology in the setting of HCT trials are included at the end of the Future Directions section.
Obesity and cancer
The relationship between obesity and the pathogenesis and treatment of cancer is complex (Table 1) . 17 As noted above, adipose tissue is the source of multiple adipokines, cytokines and other factors that affect circulating hormone levels, all of which may have profound pleiotropic effects, both on tumor biology and the efficacy and safety of therapeutics. Obesity is associated with increases in insulin, IGF-1, leptin and IL-6; decreases in adiponectin and increases in aromatase activity accounting for increased conversion of testosterone to estradiol, which can promote both breast and endometrial cancer. [36] [37] [38] Elevated insulin levels in obese patients result in decreased levels of IGF-binding protein, thereby further increasing the biologically available active factor IGF-1. Both insulin and IGF-1 promote cell growth and proliferation in normal and malignant cells by binding to the insulin receptor, the IGF-1 receptor and/or hybrid receptors and stimulating the PI3K-Akt-mTOR cellular proliferation pathway. 39, 40 Leptin and adiponectin are adipokines synthesized and secreted by adipocytes with increasing adipocyte mass resulting in 41, 42 Leptin stimulates cell and tumor growth through the leptin receptor, activating the STAT3/MAPK pathway. 43, 44 These growth factors, insulin, IGF-1, leptin and others, are capable of intracellular crosstalk, activating each other's pathways, and transactivation of epidermal growth factor pathways, 45 suggesting that even lowlevel elevations of each factor potentially may synergize to stimulate cell growth. Adiponectin binds one of the two adiponectin receptors resulting in inhibition of cell and tumor growth and stimulation of apoptosis. 46, 47 Obesity-associated risk for hematologic malignancy Importantly, insulin receptors have been identified on human ALL, AML, APL, CML and CLL cells. 48, 49 In particular, high levels of insulin receptor expression have been identified in CLL cases with deletion of 11q where ex vivo stimulation with insulin activates the AKT-mTOR and Ras/Raf/Erk pathways. 49 IGF-1 receptors have been identified on both myeloid and lymphoid leukemia cells including ALL, AML and CML, associated with increased expression of the PI3K/Akt-mTOR pathway. [49] [50] [51] [52] Similarly, leptin receptors are present on normal hematopoietic precursors and on ALL, AML, APL, and CML cells. [53] [54] [55] [56] Of interest, cells obtained during CML blast crisis have been shown to express higher levels of leptin receptors than during chronic phase. 53 The obesity-associated increase in these growth factors and the presence of their receptors, sometimes expressed at increased levels on malignant hematopoietic cells, provides an important potential mechanism by which obesity may stimulate leukemic cell growth and may contribute to the obesity-associated increased risk for some of these malignancies. Moreover, elevated circulating concentrations of these factors in obese patients may affect disease pathogenesis and impact upon therapeutic interventions. On the other hand, stimulation of pathways such as PI3K-AKT-mTOR indicates that chemotherapy with receptor neutralizing antibodies or novel pathway inhibitors may provide unique therapeutic opportunities for treating these diseases. [57] [58] [59] Obesity and plasma cell dyscrasias The complex relationship between obesity and the pathogenesis of lympho-hematopoietic malignancies is well illustrated by PCM. Multiple studies now have shown that obese patients, both black and white, are at increased risk for developing PCM. 4, 10, 11, 60 Obesity is associated also with an increased risk for developing the myeloma precursor, monoclonal gammopathy of undetermined significance (MGUS); however, an effect of obesity on transformation of MGUS to PCM has not been shown. 61 IL-6, which can be synthesized in several sites including adipose tissue, commonly is increased as part of the proinflammatory state associated with obesity. 62 As IL-6 is a necessary growth factor for PCM, its increase may contribute to the pathogenesis of myeloma in these patients. 63 In addition, elevations of serum IL-6 may contribute to the anemia of myeloma and other obesity-related malignancies by stimulation of hepcidin with consequent sequestration of iron stores. 64 Recent studies show that both insulin and IGF-1 also are potent myeloma growth factors and have their greatest effect on myeloma cells in the presence of insulin-IGF-1 hybrid receptors. 65 By activating the JAK/STAT pathway in myeloma cells, leptin increases the expression of genes involved with cellular proliferation. 66 Adiponectin suppresses growth and stimulates apoptosis in a variety of tumor cells including myeloma. 67 The increased leptin and decreased adiponectin in the obese subject may facilitate increased growth and resistance to apoptosis in myeloma cells. 65, 66 Recent studies showed increased myeloma tumor growth in adiponectin-deficient mice, whereas pharmacologic enhancement of circulating adiponectin suppressed myeloma growth. 68 Alteration of drug pharmacokinetics in obesity In addition to affecting disease pathogenesis, obesity also is known to alter the pharmacokinetics of cancer chemotherapeutics, through mechanisms that can include increased renal clearance, altered hepatic metabolism, increased volume of distribution for lipophilic drugs and increased protein binding of basic drugs. 69 Obesity-associated co-morbid conditions including diabetes mellitus and cardiovascular disease may further complicate therapeutic interventions, and through production of inflammatory cytokines, paradoxically may contribute to development of cancer cachexia. 70 These complex interactions in obese patients provide multiple research opportunities and have direct implications for disease management. Limited data, however, are available to guide management of obese patients undergoing cancer therapy and especially HCT.
Given the lack of evidence to guide the management of obese patients receiving cancer therapy, institutional practices vary widely. Some of the associated challenges are outlined in Table 2 . Anecdotal and informal survey data indicate that some obese patients may be excluded from some types of HCT because of a perception of increased risk for worse outcome. 71 It is also not surprising that institutions use different measurements to define obesity, different dosing strategies and different calculations for obese patients. 72 In one survey of 33 Australian HCT programs, no single methods for dose calculation of BU or CY was used in 430% of programs, highlighting the wide variability of approaches for dosing obese patients. 73 Whether this variability in institutional approaches affects transplant outcomes is unknown.
ASSESSING OBESE PATIENTS FOR HCT
Allogeneic HCT Some studies demonstrate that obesity may be an adverse risk factor for both complications and survival in allogeneic HCT (Table 3) . These studies comprise heterogeneous patient populations and utilize different assessments of body composition. Among 3827 Japanese patients receiving unrelated donor transplants registered to the Japan Marrow Donor Program, a higher BMI was associated with more acute GVHD and infections, but rates of relapse and survival were similar. 74 These data indicate that obesity increases complications of transplant, rather than consistently affecting pharmacokinetics of chemotherapy. In a combined adult and pediatric population of 322 patients receiving an allogeneic HCT at the University of Kentucky in the United States, obesity (defined as a weight 4120% of ideal body weight (IBW)) was associated with worse OS, especially among adults and those receiving an HLA-matched graft. 75 The Fred Hutchinson Cancer Research Center in the United States reported on 196 patients receiving unrelated donor transplants for chronic phase CML and found obesity was associated with a higher mortality, with a hazard ratio of 1.6 for each 25% increase in actual weight over ideal weight. 76 In contrast, among 262 patients with hematologic malignancies treated with myeloablative conditioning at the Princess Margaret Hospital in Canada, there were no consistent differences in frequency of mucositis, time to relapse or TRM for extreme quintiles of body weight. 77 Navarro et al. 79 reported on the outcomes of 336 patients from two transplant centers in the United Kingdom with various hematologic malignancies and found no influence of body weight on outcome aside from an increased risk of infection in the overweight and obese groups compared with normal weight. The CIBMTR investigators also have reported on the outcomes of children with severe aplastic anemia and demonstrated lower 1-and 2-year survival rates for overweight compared with lowerweight children (60 and 59% vs 470). 80 These studies are difficult to compare for several reasons. Many reports are retrospective in nature, used differing definitions of obesity, included both adults and children, and used different preparative regimens and allogeneic graft sources. Two studies, however, showed an increased risk of post-transplant infections. 78, 79 Notably, in the studies that had homogenous patient populations, there was either an increased risk of non-relapse mortality or inferior survival in overweight or obese patients. It seems clear that obesity results in adverse outcomes in the allogeneic HCT setting.
Autologous HCT In autologous HCT, outcomes across studies also are variable (Table 4) . Among 473 patients at Stanford University in the United States receiving autologous HCT for hematopoietic malignancies, a higher BMI was associated with increased non-relapse mortality but no difference in relapse rate. 81 Among 54 patients treated with high-dose BU and CY for AML in first CR at the University La Sapienza in Rome, Italy, a BMI of X27.5 was associated with an increase in TRM (33% vs 8%), with correspondingly worse OS. 82 This group also reported a significant increase in infections in obese vs non-obese patients, 78% vs 44%. In a single-center study from Turin, Italy, 121 patients with non-Hodgkin lymphoma (predominately first-line treatment recipients) given an intensive chemotherapy regimen incorporating high-dose chemotherapy with autologous HCT, a BMI over 28 was associated with worse OS and PFS. 83 In these single institution studies, a higher BMI was associated with increased toxicity, including infections and TRM, as well as inferior survival.
Two large registry studies have shown contrasting results compared with the single-center studies. A study of 4681 Hodgkin and non-Hodgkin lymphoma patients undergoing autologous HCT showed no evidence of increased TRM among overweight (BMI 25.1-30) or obese (BMI430) patients. 84 In fact, OS was superior in the more obese patients, with a hazard ratio of 0.87 for overweight patients and 0.76 for obese patients. Similarly, Vogl et al. 85 reporting from the CIBMTR on 1087 patients with PCM receiving high-dose melphalan as conditioning for autologous HCT, there was no evidence of inferior outcomes for patients with a higher BMI. Treatment outcomes among different BMI groups were similar for patients receiving high-dose melphalan alone, the most common regimen in current clinical practice. In the subgroup of patients receiving conditioning with melphalan and TBI, obese (BMI 30-34.9) and severely obese (BMI X35) patients had lower relapse rates than normal-weight (BMI 20-24.9) patients, resulting in improved PFS and OS. These two studies suggest that obese lymphoma and PCM patients undergoing autologous HCT experience equivalent toxicity and equal, perhaps superior, outcomes.
CHEMOTHERAPY DOSING RECOMMENDATIONS
Chemotherapy dosing in non-transplant patients Chemotherapy doses are most commonly calculated based on weight or body surface area, resulting in higher doses for obese patients. A common practice by oncologists, however, is to reduce doses for obese patients, either by using a lower measure of body weight (such as ideal or adjusted IBW) or by capping the maximum dose of chemotherapy at some arbitrary number. These common practices may lead to overdosing or underdosing of obese patients, with the effect potentially differing for individual chemotherapy agents. The literature on the effects of conventional chemotherapy dosing in obese patients is considerably more extensive than in the HCT setting.
Unfortunately, there is little evidence to guide dosing in obese patients as described in a recent American Society of Clinical Oncology (ASCO) Guideline. 86 Inconsistent data indicate that obese patients generally clear chemotherapy agents more slowly but experience both less efficacy and less toxicity. In obese patients with cancer, pharmacokinetic studies have shown an increased elimination half-life for CY, 87 ifosfamide, 88 oral BU, 89 and doxorubicin. 90 The delayed clearance in obese patients could suggest a need for further dose reduction, but these studies are not sufficiently powered to correlate pharmacokinetic alterations with changes in toxicity or antitumor efficacy. In early-stage breast cancer patients receiving adjuvant chemotherapy, a higher BMI correlates with reduced treatment-related toxicity, shorter time to disease recurrence, and worse OS. These findings suggest less drug exposure among obese breast cancer patients, [91] [92] [93] [94] [95] [96] [97] [98] [99] implying the need for increasing dose in the obese. In other solid tumors, higher BMI has had no consistent effect on treatment toxicity, disease recurrence or overall mortality. [100] [101] [102] The Southwest Oncology Group recently reported on the outcome of 1974 newly diagnosed patients with AML, given induction therapy based on actual body weight. They found that obese patients (defined by WHO criteria) had increased CR rates, but similar rates of OS. There was no association with BMI and toxicity in this AML population. 103 The ASCO guidelines note that there is no evidence for increased toxicity when obese patients are treated using conventional chemotherapy doses calculated using actual weight. They note that myelosuppression is either the same or less in obese patients compared with lean subjects when given full weight-based doses. These observations suggest that actual weight-based dosing in obese patients may provide the marrow with equal or reduced exposure to chemotherapy. On the basis of these observations, the ASCO guideline document recommends full weight-based dosing for obese patients, especially when the goal of treatment is cure. Unfortunately, these recommendations are based largely on 'lower quality', that is non-randomized, controlled trials in non-HCT patients.
Chemotherapy dosing in HCT patients: modification vs actual weight To better understand the discrepancies described above in the section on Assessing Obese Patients for HCT, it is important to examine how dosing was determined. In allogeneic HCT, investigators at the Princess Margaret Hospital in Ontario used IBW as determined from insurance tables to calculate chemotherapy doses; they reported no differences in the frequency of mucositis, time to relapse or TRM in extreme quintiles of body weight. 77 However, the study was underpowered to detect such differences and only assessed mucositis as present or absent, potentially missing variability in the severity of treatment complications. Investigators from Stanford utilized adjusted IBW (defined as ideal weight plus 40% of the difference between actual and IBW) when performing autologous HCT. 81 They demonstrated increased non-relapse mortality in patients with high BMI, implying that an even lower dose may be appropriate to limit toxicity. However, this study included patients with various hematologic malignancies and seven different conditioning regimens. Taken together, the heterogeneity of diseases and regimens in these reports make it difficult to draw conclusions about dosing in any individual patient. There have been only two studies with uniform diseases and treatments. In AML patients receiving BU-CY, dosed on actual body weight, the increased TRM suggests the need for dose reduction. 82 In PCM patients receiving widely variable melphalan doses, there was no clear relationship between dose reduction and transplant outcomes. 85 These findings suggest that a better understanding of the pharmacokinetics and pharmacodynamics of melphalan are needed.
The group at the University of Pennsylvania reported preliminary results from a pharmacokinetic study of high-dose melphalan in 41 patients with PCM. 104 They found a wide variability of melphalan exposure based on area under the curve with a range of 7-27 mg*h/L and a correlation between melphalan exposure and the severity of oral mucositis. They previously reported from the same patient cohort that subjects with higher body fat percentage as measured by dual energy X-ray absorptiometry scan have more severe mucositis when chemotherapy doses are calculated according to adjusted body weight (which was defined as IBW plus 25% of the difference between actual and IBW). [105] [106] [107] Analyses are ongoing to determine whether this effect is mediated by higher chemotherapy exposure. Data such as these have the potential to direct chemotherapy dosing for obese patients in the future. Nonetheless, if the goal is 'cure', clinicians and patients alike must accept more mucositis. A strategy for developing HCT dosing with curative intent in obese patients, based on quantitative assessment of fat mass and pharmacokinetics, is outlined under 'Future Directions' below.
APPROACHING PATIENTS AFTER BARIATRIC SURGERY
Along with the rise of obesity there has been an increase in the number of patients who have undergone bariatric surgery, estimated to be over 220 000 procedures in US annually. 108 Profound physiologic effects follow these surgeries extending beyond reversal of the metabolic disorders, including a reduction in cancer risk. 109, 110 There appears to be no literature on postbariatric surgery patients undergoing HCT, although there are data on altered pharmacokinetics of orally administered drugs in these patients. Bypassing the stomach and a majority of the small intestine results in decreased surface area for absorption, a more alkaline environment, elimination of a site of CYP3A first passmetabolism and lower bioavailability of extended release preparations, among numerous other effects, that may alter a drugs therapeutic and toxic effects. 111 In a recent systematic review of gastric bypass recipients, the three immunosuppressive drugs commonly used in allogeneic HCT (tacrolimus, sirolimus and mycophenolate) were shown to have significantly different pharmacokinetic parameters compared with non-bypass Obesity in HCT BM Weiss et al subjects. 112 In addition, it is important to consider the nutritional state in post-bariatric surgery patients as these patients are at increased risk for deficiencies of essential nutrients that have significant effects on the hematopoietic and skeletal systems. Deficiencies of iron, vitamin B-12, folate and copper may lead to cytopenias. In fact, there are case series of 'myelodysplastic syndrome' patients referred for HCT who, in fact, had copper deficiency due to gastrointestinal surgery that reversed with repletion of this metal. 113 Vitamin D deficiency also is common in these patients, particularly relevant for PCM patients receiving long-term corticosteroids who also are at risk of fractures and osteoporosis. 114, 115 Until evidence becomes available, we suggest that patients who present for HCT after bariatric surgery should have a baseline assessment of their nutrient and mineral status and a consultation with a nutritionist. In addition, it is critical to involve pharmacists experienced in the care of HCT patients to assist with drug dosing and monitoring. If unexpected events regarding efficacy or toxicity are encountered, the physician should consider issues of nutrition status, altered drug pharmacokinetics, or the combination as potential contributors. A multidisciplinary approach including the transplant physician, an endocrinologist, nutritionist and pharmacist is recommended in the management of HCT patients who previously have undergone bariatric surgery.
Exercise in the setting of HCT Consequences of the high doses of chemotherapy employed in HCT, including anemia, weakness and fatigue, are likely to cause reduced physical activity, decreased cardiovascular fitness, bone mineral loss and loss of muscle tone and fibers. 116 These complications can be counteracted by a regular program of progressively increasing physical activity and exercise designed to maintain aerobic capacity and cardiovascular fitness, regain strength and prevent bone loss. 117 Exercise programs may contribute to improved quality of life and may help prevent further weight gain in obese patients. Both aerobic and resistance exercise training programs have been successfully implemented during 118, 119 and after administration of the transplant regimen as well as extending over the entire course. 117, 118 Studies of exercise during the transplantation process have generally shown stabilization of status 120, 121 whereas studies of exercise during the post-transplant period have generally produced beneficial physical and psychological effects. [119] [120] [121] [122] [123] These activities should be implemented under the supervision of an experienced American College of Sports Medicine/American Cancer Society certified cancer exercise trainer. Moreover, the trainer should function as part of the transplant team. Currently, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) is performing a randomized trial of exercise, stress management or the combined interventions versus standard care in patients undergoing autologous or allo-SCT (https://web.emmes.com/ study/bmt2/protocol/0902_protocol/0902_protocol.html).
FUTURE DIRECTIONS
Future studies addressing obesity in the setting of HCT should address the following issues outlined in Table 5 . A more consistent and biologically relevant definition of obesity should be used across studies. Investigators participating in the current BMT CTN 0702 trial for newly diagnosed PCM patients undergoing highdose melphalan and autologous HCT prospectively are measuring BMI and waist-to-hip ratio at three time points during the first year after HCT. These measurements will be correlated with melphalan dose, infused CD34 þ cell dose, toxicity and outcomes, the first such study prospectively to evaluate anthropomorphic measurements in a uniformly treated HCT patient population.
The highly toxic levels of chemotherapy administered as conditioning regimens in HCT are justified by the curative intent of the procedure. Lipophilic chemotherapeutic agents, however, may become sequestered in adipose tissue, potentially reducing circulating blood concentrations and compromising their curative capacity in obese patients. Use of IBW to calculate dose in obese patients reduces the likelihood of toxicity but risks underdosing and reducing antitumor effects and curative outcomes; calculating dose based on actual body weight may result in overdosing and improving antitumor effect but increasing toxicity. Given the problems associated with available data upon which to base HCT dosing schedules, it seems prudent to adopt guidelines as outlined above, where chemotherapy doses in the obese HCT patient were calculated according to adjusted IBW (defined as IBW plus 25% of the difference between actual and IBW). With this dose schedule as a starting point, there is an urgent need for doseescalation studies with pharmacodynamics and pharmacokinetics of agents used in HCT. These variables can be correlated with fat tissue mass quantitatively as measured by MRI scan and evaluated relative to clinical parameters of graft rejection, acute and chronic toxicity, time to recurrence, disease-free survival and OS.
Of the physical measurements noted above, height and weight, used to calculate BMI, are probably the least subject to investigator bias or variability. In contrast, waist, hip and skin fold measurements are highly subject to investigator variability. Accordingly, we recommend using the WHO criteria to identify and stratify patients according to BMI status as underweight, normal, overweight and obese. Although the WHO criteria are useful for stratifying according to BMI, we recommend use of modern imaging technology, preferably MRI for the basis of clinical trials especially those involving HCT. Although MRI cost is high, the measurement does not involve ionizing radiation and can be used repeatedly, although most importantly before initiation of chemotherapy. Moreover, MRI provides identification Table 5 . Recommendations for future studies of HCT in obese patients Use adjusted ideal body weight for dose calculation for research studies of HCT with curative intent. Employ quantifiable, reproducible, investigator-independent techniques, e.g., DEXA or MRI scans to measure total body adipose tissue mass (allows segmentation according to anatomic distribution). Evaluate PK and PD of chemotherapeutic agents relative to weight and quantitative measurements of total and compartmental adipose tissue masses. Evaluate specific components of clinical response relative to PK, PD and adipose tissue mass. To include: (1) antitumor effect; (2) acute and chronic toxicities including TRM; (3) engraftment kinetics; (4) relapse rate and time to progression; (5) time, cause and rate of NRM. Measure obesity-associated biomarkers and mediators to identify relation to clinical course and outcome. Focus on: insulin, c-peptide, IGF-1, I GF-BPs, leptin, adiponectin, IL-6, hepcidin, TNF-a, CRP. Study impact of graduated increase in aerobic and resistance exercise on obesity and patient outcomes. Integrate dose-escalation studies with curative intent and include PK, PD, biomarkers and assessment of adipose tissue mass; evaluate relative to patient outcomes.
Abbreviations: CRP ¼ C-reactive protein; DEXA ¼ dual energy X-ray absorptiometry; IGF-BP ¼ insulin-like growth factor-binding protein; NRM ¼ non-relapse mortality; PD ¼ pharmacodynamics; PK ¼ pharmacokinetics.
of clear and quantitative definitions of different body mass volumes, fat, lean and bone mineral, as well as distribution of adipose tissue between visceral and subcutaneous depots. These parameters can then be used to analyze and explain potentially variable results from different patients on an individual basis.
CONCLUSIONS AND RECOMMENDATIONS
The association of obesity with an increased risk of malignancy has forced physicians routinely to consider both the risks of HCT for obese patients and how to dose chemotherapy. The available data are largely observational and can be difficult to interpret due to variability in definitions of obesity, patient populations, chemotherapy regimens and dosing calculations. It seems clear, however, that obesity results in adverse outcomes in the allogeneic HCT setting and should be incorporated into the risk-benefit assessment in patients being considered for the transplantation procedure. Conversely, in the setting of autologous HCT for PCM and lymphoma, obesity does not appear to adversely affect outcomes and should not be considered a contraindication to treatment. The available data do not justify a specific recommendation on dosing strategy for the obese, but the commonly used strategies of dosing according to adjusted IBW appear to be reasonable to best achieve curative intent while providing the basis for further dosedevelopment clinical trials. Further research should provide a more rational and more precise basis for recommendations predicated on curative intent. The rising prevalence of obesity emphasizes the urgency of this research.
